Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Gastroenterol Hepatol ; 32(3): 602-608, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-27548332

RESUMO

BACKGROUND AND AIM: Fluorine-18 2-fluoro-2-deoxy-d-glucose positron emission tomography (PET) is effective and less invasive than other modalities used to diagnose tumors, including colorectal cancer (CRC). However, the detectability of adenomas and CRCs, especially in the early stages, is unclear. METHODS: We evaluated the records of 2323 consecutive eligible patients who underwent both a total colonoscopy (TCS) and PET between October 2002 and September 2012 at a tertiary cancer center. The PET findings were verified by TCS performed independently within 1 year. Target lesions were defined as CRCs and adenomas that were 6 mm or larger in size. RESULTS: Total colonoscopy detected 532 target lesions ≥ 6 mm in size: 56 T2-T4 CRCs, 39 T1 CRCs, 223 advanced adenomas, and 214 low-grade adenomas. Of the 532 lesions, 216 (40.6%) were PET positive. Of the 369 cases with positive uptakes, PET detected target lesions in the matched segments for 58.5% (216/369). Sensitivity of PET to T2-T4 CRCs, T1 CRCs, advanced adenomas, and low-grade adenomas was 92.9%, 79.5%, 50.7%, and 9.3%, respectively. PET could detect 76.5% (13/17) of T1 CRCs whose size is 10 to 19 mm and 85.0% (17/20) of T1 CRCs equal or larger than 20 mm. The multivariate analysis excluding T2-T4 CRCs showed malignant histology, larger size, protruded lesions, villous histology, and lesions in distal colon were significant factors. CONCLUSIONS: Sensitivity of PET for detecting T2-T4 and even T1 cancers are promising. However, sensitivity of PET to adenomas, even advanced adenomas, is limited.


Assuntos
Adenoma/diagnóstico por imagem , Neoplasias Colorretais/diagnóstico por imagem , Tomografia por Emissão de Pósitrons , Adenoma/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Colonoscopia , Neoplasias Colorretais/patologia , Feminino , Radioisótopos de Flúor , Fluordesoxiglucose F18 , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Compostos Radiofarmacêuticos , Sensibilidade e Especificidade , Adulto Jovem
2.
Hepatol Res ; 43(5): 475-80, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23046493

RESUMO

AIM: The aim of this retrospective study was to compare the local control effects of transcatheter arterial chemoembolization (TACE) using epirubicin (EPIR) and that using miriplatin (MPT) for hepatocellular carcinoma (HCC). METHODS: Between January 2010 and July 2011, 218 HCC cases were treated with TACE, including 69 cases using EPIR or MPT as initial treatment. All 69 patients were treated with iodized oil and gelatin sponge particles. The local control rate (modified Response Evaluation Criteria in Solid Tumors [RECIST] ver. 1.0), time to treatment failure (Kaplan-Meier and log-rank test) and adverse events were evaluated. RESULTS: Forty-two cases were treated using EPIR, and 27 cases were treated using MPT. All 69 patients had no previous treatment with TACE or hepatic arterial infusion. No serious adverse events were observed in either group. The response rates, including complete response (CR) and partial response (PR), of the EPIR group and the MPT group were 85.7% and 81.5%, respectively, with a time to treatment failure of 5.1 and 7.5 months, respectively. Excluding whole liver TACE cases, time to treatment failure was 5.4 months for the EPIR group and 10.1 months for the MPT group. CONCLUSION: In TACE naïve cases, there was no significant difference in local control between EPIR and MPT.

3.
Surg Today ; 42(2): 200-4, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22160355

RESUMO

We report a case of hepatocellular adenoma, focusing on the findings of liver-specific contrast agent-enhanced magnetic resonance imaging (MRI) and ¹8F-fluorodeoxyglucose positron emission tomography (FDG-PET). The patient was a 37-year-old woman, referred to us after contrast-enhanced computed tomography showed a homogeneous, poorly enhanced liver tumor, 2.8 cm in diameter. Magnetic resonance imaging showed a liver mass with significant fatty change. The tumor increased in size to 3.3 cm over 9 months of follow-up. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI revealed spotty enhancement in the hypointense tumor in the hepatobiliary phase. Subsequent FDG-PET showed increased uptake of FDG (maximum standardized uptake value 5.0), which suggested the possibility of malignancy. The patient underwent partial hepatectomy, and histological examination of the resected specimen revealed a tumor composed of hepatocyte-like cells with minimal cellular atypia and significant diffuse fatty change. Based on these findings, we diagnosed hepatocellular adenoma.


Assuntos
Adenoma de Células Hepáticas/diagnóstico , Fluordesoxiglucose F18 , Neoplasias Hepáticas/diagnóstico , Imageamento por Ressonância Magnética/métodos , Tomografia por Emissão de Pósitrons/métodos , Compostos Radiofarmacêuticos , Adenoma de Células Hepáticas/cirurgia , Adulto , Diagnóstico Diferencial , Feminino , Seguimentos , Hepatectomia , Humanos , Fígado/diagnóstico por imagem , Fígado/patologia , Neoplasias Hepáticas/cirurgia , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA